Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.

Cancer Biology & Therapy
Weixin Wang, William D Figg

Abstract

Tumor suppressor BRCA1 and BRCA2 are frequently mutated in familial breast and ovarian cancer. More than ten percent of women with breast or ovarian cancer carry BRCA1 or BRCA2 (BRCA1/2) mutations. Cancers that arise in mutation carriers have often lost the wild-type allele through somatic alterations during tumor progression. BRCA1/2 play important roles in homologous recombination repair of DNA double-strand breaks. Because of this, BRCA1/2-deficient cancers often have a better response to DNA cross-linking agents such as platinum analogues and to poly(ADP-ribose) polymerase (PARP) inhibitors. However, over time, the majority of these BRCA1/2-deficient cancers become resistant and patients die from refractory diseases. Three recent studies demonstrated that acquired resistance to platinum analogues or PARP inhibitors in tumors carrying frame-shift BRCA1/2 mutations came from restored BRCA1/2 expression and HR function due to secondary intragenic mutations that corrected the open reading frames of mutated BRCA1/2.

Citations

Dec 14, 2011·Journal of Molecular Cell Biology·Libing SongJun Li
Feb 1, 2011·Journal of Molecular Cell Biology·Amal Aly, Shridar Ganesan
Nov 17, 2015·Expert Review of Anticancer Therapy·Priya SamuelDavid RaulFrancisco Carter
Dec 17, 2009·Biochemical Pharmacology·Giovanni Luca BerettaPaola Perego
Oct 20, 2009·European Journal of Pharmacology·Zbigniew DarzynkiewiczDonald Wlodkowic
Sep 8, 2010·The Journal of Pathology·Soo-Youn Lee, Howard L McLeod
Feb 22, 2011·Journal of Surgical Oncology·David M Euhus
Sep 19, 2014·World Journal of Gastroenterology : WJG·Jun NakamuraKohji Miyazaki
Dec 1, 2017·Cancer Chemotherapy and Pharmacology·Xiaojun LiuWilliam Plunkett
Oct 6, 2020·Frontiers in Cell and Developmental Biology·Maddison RoseEmma Bolderson
Jul 9, 2009·Molecular Cancer Research : MCR·Fan ZhangPaul R Andreassen
Jun 28, 2011·Molecular Cancer Research : MCR·Paola De LucaAdriana De Siervi
Jun 5, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Purificacion Estevez-GarciaAmancio Carnero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.